AstraZeneca PLC (AZN)vsPuma Biotechnology Inc (PBYI)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
PBYI
Puma Biotechnology Inc
$9.12
-0.55%
HEALTHCARE · Cap: $492.97M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 26437% more annual revenue ($61.37B vs $231.24M). AZN leads profitability with a 17.0% profit margin vs 11.6%. PBYI appears more attractively valued with a PEG of 0.03. PBYI earns a higher WallStSmart Score of 67/100 (B-).
AZN
Buy60
out of 100
Grade: C+
PBYI
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+68.6%
Fair Value
$21.16
Current Price
$9.12
$12.04 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Growing faster than its price suggests
Conservative balance sheet, low leverage
Earnings expanding 35.8% YoY
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : PBYI
The strongest argument for PBYI centers on PEG Ratio, Debt/Equity, EPS Growth. PEG of 0.03 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : PBYI
The primary concerns for PBYI are Market Cap, Altman Z-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while PBYI is a value play — different risk/reward profiles.
PBYI carries more volatility with a beta of 1.23 — expect wider price swings.
PBYI is growing revenue faster at 7.8% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
PBYI scores higher overall (67/100 vs 60/100). AZN offers better value entry with a 18.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Puma Biotechnology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?